Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
about
Genomic landscape of human papillomavirus-associated cancersAntiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerEpidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancerPotential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review.Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma.Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience.Somatic mutation in PIK3CA is a late event in cervical carcinogenesis.Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceGrowth factor progranulin promotes tumorigenesis of cervical cancer via PI3K/Akt/mTOR signaling pathway.Somatic Host Cell Alterations in HPV Carcinogenesis.The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy.Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.Determination of Puquitinib in Human Plasma by HPLC-ESI MS/MS: Application to Pharmacokinetic Study.Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer
P2860
Q26997399-A2665335-5097-4A5A-A760-705FB4B98F9AQ33779691-585B1524-AE4B-4520-A9BA-32F36BA697E8Q35885555-11A58EF7-97D6-4BE3-A799-5F5C6129A402Q36049360-EB847F0D-C770-48B6-9823-6768E0CB116CQ36206239-2222E5D7-3580-4974-9D63-694410C9A081Q36685569-5E9032C6-2716-4924-8580-09A4D9B3040CQ36937086-480AA58A-58DC-42B5-BA6A-CBD4561C04B6Q37082560-96B9EDDA-1957-4A9B-95E8-BC72A748A043Q37376481-562CA98A-9458-43EA-A446-2FFDCC1DEF55Q37401006-B16D6BBA-B5E2-4385-AAA4-4FE5641889D4Q37577932-DF34DE50-2E41-484F-ADED-EEF663B35BECQ37629030-F6AB56B1-298A-4E22-88F9-EA2B376C7C58Q40096622-A1AA31F9-2F45-48FD-8140-87140D4800C4Q48185689-B977AF75-ED6F-4665-A510-708E71AD2B6DQ49228103-EC57AAAA-9457-44C5-8327-AC5BFB2E75F5Q52607328-B4D74AEA-6FED-445E-9594-F1801C916562Q52665380-BC1F353A-4F17-44F1-A266-095ADAD5DA25Q57117154-AC8257DC-F164-4483-9C13-8403DB030DA0
P2860
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@ast
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@en
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@nl
type
label
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@ast
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@en
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@nl
prefLabel
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@ast
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@en
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeted PI3K/AKT/mTOR therapy ...... A phase I clinical experience.
@en
P2093
David Hong
Jennifer Wheler
Ming-Mo Hou
Ralph Zinner
Robert L Coleman
Xiaochun Liu
P2860
P304
11168-11179
P356
10.18632/ONCOTARGET.2584
P407
P577
2014-11-01T00:00:00Z